Global Pneumococcal Vaccine Market Size, Share & Trends Analysis Report, By Vaccine Type (Pneumococcal Conjugate Vaccine (PCV13), Pneumococcal Polysaccharide Vaccine (PPSV23), Others), By Distribution Channel (Public, and Private), By Type (Branded and Generic), By Age Group (Children and Adult) and Forecast, 2020-2026.
The pneumococcal vaccine market is anticipated to grow at a CAGR of around 4.0% during the forecast period 2020-2026. High prevalence of pneumonia among children and significant private and public spending to curb the disease is the major factor for the growth of the market Besides, development in the healthcare infrastructure in the emerging economies coupled with growing awareness toward vaccination is also augmenting the market growth.
The global pneumococcal vaccine market is segmented based on the vaccine type, distribution channel, type, and age group. On the basis of vaccine type, the market is divided into Pneumococcal Conjugate Vaccine (PCV13), Pneumococcal Polysaccharide Vaccine (PPSV23), and others. PCV13 is anticipated to have a major market share during the forecast period.
The global pneumococcal vaccine market is divided into four regions, including North America (the US, Canada), Europe (Germany, UK, France, Spain, Italy), Asia-Pacific (China, India, Japan), and the Rest of the World (RoW). North America holds the largest market share during the forecast period. The high cost of the drug and developed healthcare infrastructure are some of the major factors for the growth of the market in the region. Moreover, significant opportunities will be witnessed in Asia-Pacific owing to increasing vaccine manufacturers in the region such as the Serum Institute of India in India and Walvax Biotechnology Co., Ltd in China.
Pneumococcal vaccine is a consolidated market and key players actively working in the pneumococcal vaccine market include Pfizer Inc., Sanofi SA, GlaxoSmithKline PLC, Serum Institute of India Pvt. Ltd., Merck & Co., Inc., Walvax Biotechnology Co., Ltd., CSL Ltd., and Astellas Pharma Inc. The market players are adopting growth strategies, including mergers and acquisitions, product launches, and partnerships & collaborations, to gain a competitive advantage in the market.
Research Methodology
The market study of the global Pneumococcal vaccine market is incorporated by extensive primary and secondary research conducted. Secondary research has been conducted to breakdown the market in various segments; derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.
In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts to amplify the added validity of the reports.
Secondary Sources Include
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
The Report Covers
The pneumococcal vaccine market is anticipated to grow at a CAGR of around 4.0% during the forecast period 2020-2026. High prevalence of pneumonia among children and significant private and public spending to curb the disease is the major factor for the growth of the market Besides, development in the healthcare infrastructure in the emerging economies coupled with growing awareness toward vaccination is also augmenting the market growth.
The global pneumococcal vaccine market is segmented based on the vaccine type, distribution channel, type, and age group. On the basis of vaccine type, the market is divided into Pneumococcal Conjugate Vaccine (PCV13), Pneumococcal Polysaccharide Vaccine (PPSV23), and others. PCV13 is anticipated to have a major market share during the forecast period.
The global pneumococcal vaccine market is divided into four regions, including North America (the US, Canada), Europe (Germany, UK, France, Spain, Italy), Asia-Pacific (China, India, Japan), and the Rest of the World (RoW). North America holds the largest market share during the forecast period. The high cost of the drug and developed healthcare infrastructure are some of the major factors for the growth of the market in the region. Moreover, significant opportunities will be witnessed in Asia-Pacific owing to increasing vaccine manufacturers in the region such as the Serum Institute of India in India and Walvax Biotechnology Co., Ltd in China.
Pneumococcal vaccine is a consolidated market and key players actively working in the pneumococcal vaccine market include Pfizer Inc., Sanofi SA, GlaxoSmithKline PLC, Serum Institute of India Pvt. Ltd., Merck & Co., Inc., Walvax Biotechnology Co., Ltd., CSL Ltd., and Astellas Pharma Inc. The market players are adopting growth strategies, including mergers and acquisitions, product launches, and partnerships & collaborations, to gain a competitive advantage in the market.
Research Methodology
The market study of the global Pneumococcal vaccine market is incorporated by extensive primary and secondary research conducted. Secondary research has been conducted to breakdown the market in various segments; derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.
In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts to amplify the added validity of the reports.
Secondary Sources Include
- Financial reports of companies involved in the market
- Authentic public databases
- Whitepapers, research-papers, and news blogs
- Company websites and their product catalog
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
- Global Pneumococcal Vaccine Market Research and Analysis, By Vaccine Type
- Global Pneumococcal Vaccine Market Research and Analysis, By Distribution Channel
- Global Pneumococcal Vaccine Market Research and Analysis, By Type
- Global Pneumococcal Vaccine Market Research and Analysis, By Age Group
The Report Covers
- Comprehensive research methodology of the Global Pneumococcal Vaccine Market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global Pneumococcal Vaccine Market.
- Insights about market determinants which are stimulating the Global Pneumococcal Vaccine Market.
- Detailed and extensive market segments with regional distribution of forecast revenues.
- Extensive profiles and recent developments of market players.
Table of Contents
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Determinants
5. Market Segmentation
6. Regional Analysis
7. Company Profiles
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
A selection of companies mentioned in this report includes:
- Astellas Pharma Inc.
- China National Biotec Group Company Ltd.
- CSL Ltd.
- GlaxoSmithKline PLC
- Merck & Co., Inc.
- Novavax, Inc.
- Pfizer Inc.
- Walvax Biotechnology Co., Ltd.
- SK Bioscience
- Sanofi SA
- Serum Institute of India Pvt. Ltd.
- PnuVax Incorporated
